An artist's impression of Anhui Anke Biotechnology (Group) Co Ltd's production center in the Hefei high-tech zone. [Photo/WeChat ID: hefeigaoxinfabu]

A new production base for Anhui Anke Biotechnology (Group) Co Ltd began construction on Dec 20 in the Hefei National High-tech Industry Development Zone, or Hefei high-tech zone - located in Hefei, capital of East China's Anhui province.

With a total investment of about 2 billion yuan ($286.54 million) and a planned area of 244, 739 square meters, it's the biggest antibody drug R&D and industrialization facility being built in the region.

It will involve new production plants, warehouses, comprehensive R&D buildings, as well as canteens and staff dormitories.

On completion, the production center will have annual  production capacity of 4 million antibody drugs, 50 million protein drugs and 3.75 million peptide drugs.

Moreover, it is expected to generate annual sales of about 6 billion yuan and provide 3,000 new jobs.

"Thanks to the favorable policies and a good business environment, we have entered the fast lane of development, with operating income always maintaining a compound annual growth of more than 20 percent," said Song Lihua, chairman of Anhui Anke Biotechnology (Group) Co Ltd.

Song added that the group would strengthen its research and innovation and contribute to the comprehensive development of a healthy China.